Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most MRONJ/ONJ risk-related claims align with label section 5.4 (dental exam, risk factors including invasive dental procedures and poor oral hygiene, ONJ may occur during Prolia, duration of exposure). Some items are not fully supported as stated (e.g., 'jaw pain' as an early sign, and 'longer exposure increases risk' timing framing). Discontinuation fracture-risk claims align with section 5.6, but specific transition-to-alternative therapy and clinician-led discontinuation planning are not fully reflected.
Category Scores
Accurate Statements
Prolia can be associated with medication-related osteonecrosis of the jaw (MRONJ).
Label 5.4: ONJ has been reported in patients receiving denosumab.
MRONJ is a known risk with denosumab.
Label 5.4: ONJ has been reported in patients receiving denosumab; ONJ risk discussion is in boxed/label warning section.
MRONJ risk increases with invasive dental procedures.
Label 5.4: dental examination recommended prior to treatment in patients with risk factors such as invasive dental procedures (e.g., tooth extraction, dental implants, oral surgery).
MRONJ risk increases with poor oral health.
Label 5.4: poor oral hygiene is listed as a risk factor; good oral hygiene should be maintained during treatment.
MRONJ risk increases with longer exposure to Prolia.
Label 5.4: 'The risk of ONJ may increase with duration of exposure to Prolia.'
MRONJ can occur after starting denosumab therapy.
Label 5.4: 'ONJ, which can occur spontaneously... has been reported in patients receiving denosumab.'
Evaluation for suspected MRONJ may include an oral exam and imaging.
Label 5.4: patients suspected of having or who develop ONJ while on Prolia should receive care by a dentist or oral surgeon. (Oral exam/imaging is not explicitly stated; see unsupported/omission for imaging specifics.)
If MRONJ is found, management depends on severity and symptoms.
Label 5.4: For patients suspected of having or developing ONJ, management considerations include that extensive dental surgery may exacerbate; discontinuation should be considered based on individual benefit-risk assessment. (Severity/symptoms phrasing is not explicit.)
Treatment of MRONJ can include conservative care such as mouth rinses, pain control, and infection management.
Label 5.4 does not specify conservative measures (e.g., mouth rinses/pain control/infection management).
In some cases, MRONJ management can include surgical approaches.
Label 5.4: 'extensive dental surgery to treat ONJ may exacerbate the condition' implies surgery may be involved.
Prolia discontinuation can increase fracture risk in some patients.
Label 5.6: 'Following discontinuation of Prolia treatment, fracture risk increases, including the risk of multiple vertebral fractures.'
Patients should not stop Prolia on their own.
Label 5.6: 'Evaluate an individual's benefit-risk before initiating treatment' and if discontinued, patients should be transitioned to an alternative antiresorptive therapy—implies clinician-guided discontinuation rather than unsupervised stopping.
Unsupported Statements
Jaw pain can be an early sign of MRONJ.
Label 5.4 does not mention jaw pain as an early sign.
Jaw pain during Prolia treatment should be evaluated by a clinician for possible MRONJ or other causes.
Label 5.4 states that patients suspected of having or who develop ONJ should receive care by a dentist or oral surgeon, but it does not specifically instruct clinician evaluation of 'jaw pain' or 'other causes' wording.
Jaw pain during Prolia treatment should generally be assessed rather than watched for long without evaluation.
No label statement about 'jaw pain' needing prompt assessment vs monitoring.
MRONJ risk increases with longer exposure to antiresorptive therapy.
Label 5.4 discusses duration of exposure to Prolia; it does not state 'longer exposure to antiresorptive therapy' in general.
MRONJ timing varies depending on the presence of triggers such as invasive dental work.
Label 5.4 does not discuss timing variation for MRONJ relative to triggers.
Clinicians typically assess the jaw for signs of MRONJ and other causes of dental pain.
Label 5.4 recommends oral/dental examination and that suspected/developed ONJ be managed by a dentist/oral surgeon, but does not state this general workflow or 'other causes of dental pain' language.
Evaluation for suspected MRONJ may include an oral exam and imaging.
Label 5.4 recommends dental examination/preventive dentistry and care by a dentist/oral surgeon but does not mention imaging.
Treatment plan depends on whether MRONJ is suspected and how extensive it is.
Label 5.4 provides individual benefit-risk assessment and notes extensive dental surgery may exacerbate condition; it does not explicitly frame decisions by 'how extensive' MRONJ is.
Your dentist and prescribing clinician may coordinate care, particularly if invasive dental work is involved.
Label 5.4 states clinical judgment of treating physician and/or oral surgeon guides management plan; coordination language with dentist/prescriber is not explicit.
Patients taking Prolia (or who have taken it recently) should tell their dentist and surgeon before extraction, implant, or other invasive procedures.
Label 5.4 does not explicitly instruct patients to notify dentist/surgeon before procedures or address 'recent' dosing.
Prevention and planning may include timing dental work around the Prolia dosing schedule.
Label 5.4 recommends dental examination and preventive dentistry prior to treatment and for risk factor patients, but does not state timing procedures around dosing.
Prolia patients may need addressing of infection or non-restorable teeth when possible as part of dental planning.
Label 5.4 does not specify addressing infection or non-restorable teeth.
A clinician may advise whether and when to adjust Prolia treatment in coordination with dental care.
Label 5.4 says discontinuation should be considered based on individual benefit-risk assessment, but does not describe adjusting 'when' or coordination framework.
Treatment of MRONJ can include conservative care such as mouth rinses, pain control, and infection management.
Label 5.4 does not list specific conservative treatments.
Contradictions
Important Omissions
Routine oral exam should be performed by the prescriber prior to initiation of Prolia; dental exam with preventive dentistry recommended prior to treatment in patients with risk factors.
Importance:
Moderate
Good oral hygiene practices should be maintained during treatment.
Importance:
Moderate
Concomitant administration of drugs associated with ONJ may increase ONJ risk.
Importance:
Moderate
For patients suspected of having or who develop ONJ while on Prolia: care by a dentist or oral surgeon; extensive dental surgery may exacerbate condition; discontinuation should be considered based on individual benefit-risk assessment.
Importance:
Moderate
If Prolia is discontinued, patients should be transitioned to an alternative antiresorptive therapy.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Some specific clinical instructions (jaw pain as early sign; conservative management details; imaging; timing around dosing) are not supported by the provided label text. However, core ONJ risk factors and the discontinuation fracture-risk concept are largely aligned; key missing label element is transition to alternative antiresorptive therapy if discontinued.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several statements (e.g., jaw pain as an early sign, imaging, conservative care specifics, timing around dosing, patient notification before procedures) are not explicitly supported by the provided label sections; omission of transition-to-alternative antiresorptive therapy after discontinuation is important.
Suggested Improvement
Restrict claims to label-supported points in 5.4 (routine oral exam prior to initiation; preventive dentistry for risk factors; maintain good oral hygiene; ONJ reported with denosumab; risk may increase with duration; invasive dental procedures and poor oral hygiene as risk factors; dentist/oral surgeon management; discontinuation considered via benefit-risk assessment) and 5.6 (discontinuation increases fracture risk; transition to alternative antiresorptive therapy if discontinued).